Coherus rises after liver cancer treatment shows promise in mid-stage study

Coherus Oncology

19/01/2024 11:48

** Shares of drug maker Coherus BioSciences  CHRS.O  rise
5.8% to $2.54 premarket
    ** Late Thursday, co said its experimental cancer therapy
casdozokitug in combination with Roche's  ROG.S  cancer drugs
atezolizumab and bevacizumab reduced tumors in up to 43% of
patients of hepatocellular carcinoma in a mid-stage study
    ** The combination treatment also showed complete
disappearance of tumors in three patients
    ** The treatment also met its main goal of safety and
tolerability
    ** Hepatocellular carcinoma is the most common form of liver
cancer
    ** Up to Thursday's close, stock was down 73.2% in the last
12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))